Specific Inhibition of Tumor Cells by Oncogenic EGFR Specific Silencing by RNA interference

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Takahashi, Masaki ^a   Chiyo, Tomoko ^a   Okada, Takashi ^a   Hohjoh, Hirohiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; SMALL INTERFERING RNA;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EGFR GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; ONCOGENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENETIC THERAPY; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84881324260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073214     Document Type: Article

References (24)

1. Mitsudomi T, Yatabe Y, (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277: 301-308. doi:10.1111/j.1742-4658.2009.07448.x. PubMed: 19922469.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
3. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181. doi:10.1038/nrc2088. PubMed: 17318210.
4. Irmer D, Funk JO, Blaukat A, (2007) EGFR kinase domain mutations- functional impact and relevance for lung cancer therapy. Oncogene 26: 5693-5701. doi:10.1038/sj.onc.1210383. PubMed: 17353898.
5. Pines G, Köstler WJ, Yarden Y, (2010) Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 584: 2699-2706. doi:10.1016/j.febslet.2010.04.019. PubMed: 20388509.
6. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, et al. (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Lung Cancer 72: 3-8. doi:10.1016/j.lungcan.2010.12.009. PubMed: 21216488.
7. Hait WN, Hambley TW, (2009) Targeted cancer therapeutics. Cancer Res 69: 1263-1267; discussion 1267 doi:10.1158/0008-5472.CAN-08-3836. PubMed: 19208830.
8. Hartmann JT, Haap M, Kopp HG, Lipp HP, (2009) Tyrosine kinase inhibitors- a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481. doi:10.2174/138920009788897975. PubMed: 19689244.
9. Hohjoh H, (2010) Allele-specific silencing by RNA interference. Methods Mol Biol 623: 67-79. doi:10.1007/978-1-60761-588-0_4. PubMed: 20217544.
10. Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H, (2008) Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLOS ONE 3: e2248. doi:10.1371/journal.pone.0002248. PubMed: 18493311.
11. Ohnishi Y, Tokunaga K, Kaneko K, Hohjoh H, (2006) Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. J RNAi Gene Silencing 2: 154-160. PubMed: 19771217.
12. Takahashi M, Katagiri T, Furuya H, Hohjoh H, (2011) Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Gene Ther, 19: 781-5. PubMed: 22130450.
13. Takahashi M, Watanabe S, Murata M, Furuya H, Kanazawa I, et al. (2010) Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl Acad Sci U S A 107: 21731-21736. doi:10.1073/pnas.1012153107. PubMed: 21098280.
14. Okada T, Amanuma H, Okada Y, Obata M, Hayashi Y, et al. (1997) Inhibition of gene expression from the human c-erbB gene promoter by a retroviral vector expressing anti-gene RNA. Biochem Biophys Res Commun 240: 203-207. doi:10.1006/bbrc.1997.7563. PubMed: 9367910.
15. Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, et al. (2004) In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo. J Gene Med 6: 288-299. doi:10.1002/jgm.490. PubMed: 15026990.
16. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, et al. (2009) Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11: 373-381. doi:10.1002/jgm.1313. PubMed: 19274675.
17. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T, (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64: 3365-3370. doi:10.1158/0008-5472.CAN-03-2682. PubMed: 15150085.
18. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, et al. (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102: 12177-12182. doi:10.1073/pnas.0501753102. PubMed: 16091473.
19. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, et al. (2004) Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32: e109. doi:10.1093/nar/gnh093. PubMed: 15272050.
20. Hanai K, Takeshita F, Honma K, Nagahara S, Maeda M, et al. (2006) Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann N Y Acad Sci 1082: 9-17. doi:10.1196/annals.1348.010. PubMed: 17145919.
21. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG, (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892. PubMed: 11156248.
22. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, et al. (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754. PubMed: 12384534.
23. Gazdar AF, Shigematsu H, Herz J, Minna JD, (2004) Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10: 481-486. doi:10.1016/j.molmed.2004.08.008. PubMed: 15464447.
24. Sharma SV, Settleman J, (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231. doi:10.1101/gad.1609907. PubMed: 18079171.